Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LRRC15 Protein (AA 22-538) (His tag)

LRRC15 Origin: Human Host: HEK-293 Cells Recombinant >95 % as determined by SDS-PAGE.
Catalog No. ABIN7013689
  • Target See all LRRC15 products
    LRRC15 (Leucine Rich Repeat Containing 15 (LRRC15))
    Protein Type
    Recombinant
    Protein Characteristics
    AA 22-538
    Origin
    • 6
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Source
    • 7
    • 2
    • 1
    • 1
    • 1
    HEK-293 Cells
    Purification tag / Conjugate
    This LRRC15 protein is labelled with His tag.
    Characteristics
    Human LRRC15 / LIB Protein, His Tag (MALS verified)
    Purity
    >95 % as determined by SDS-PAGE.
    Endotoxin Level
    Less than 1.0 EU per μg by the LAL method.
  • Want other Options for this Protein ?

    !
    Discover Our Predefined Custom Proteins and Custom Protein Services!

    Your project requires further customization? Contact us and discover our custom protein solutions

  • Application Notes
    MALS verified
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Buffer
    PBS, pH 7.4
    Storage
    -20 °C
  • Target
    LRRC15 (Leucine Rich Repeat Containing 15 (LRRC15))
    Alternative Name
    LRRC15 (LRRC15 Products)
    Background
    LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.
    Molecular Weight
    59.8 kDa
You are here:
Chat with us!